Company
Catabasis Pharmaceuticals, Inc.
Headquarters: Boston, MA, United States
Employees: 20
CEO: Ms. Jill C. Milne
Market Cap
$109.5 Million
USD as of June 1, 2022
Catabasis Pharmaceuticals, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Stocks & Indices
Catabasis Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: CATB wb_incandescent
Product & Services
Orally-delivered pharmaceuticals
Key People
Jill C. Milne, Ph. D. (CEO) Joanne M. Donovan, M. D., Ph. D. (Chief Medical Officer) Andrew Nichols, Ph. D. (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer)